Company: OXLCZ
Filing Date: 2025-09-04
Form Type: DEF 14A
Source: 0001213900-25-084505
Chunk: 27

Company: Oxford Lane Capital Corp.
Filing Date: 2025-09-04
Form: DEF 14A
Chunk 27
---
 Capital. Mr. Cohen, our Chief Executive Officer, and Mr. Rosenthal, our President, through their ownership interest in Oxford Funds, the managing member of Oxford Lane Management, are entitled to a portion of any profits earned by Oxford Lane Management, which includes any fees payable to Oxford Lane Management under the terms of the Investment Advisory Agreement, less expenses incurred by Oxford Lane Management in performing its services under the Investment Advisory Agreement. Messrs. Cohen and Rosenthal do not receive any additional compensation from Oxford Lane Management in connection with the management of our portfolio. The compensation of our Chief Financial Officer, Controller, and other administrative support personnel, is paid by our administrator, Oxford Funds, subject to reimbursement by us of an allocable portion of such compensation for services rendered by our Chief Financial Officer, Controller, and other administrative support personnel, to Oxford Lane Capital. The allocable portion of such compensation that is reimbursed to Oxford Funds by us is based on an estimate of the time spent by our Chief Financial Officer, Controller, and other administrative support personnel in performing their respective duties for us in accordance with the Administration Agreement. For the fiscal year ended March 31, 2025, we accrued approximately $1,327,567 for the allocable portion of compensation expenses incurred by Oxford Funds on our behalf for our Chief Financial Officer, Controller, and other administrative support personnel, pursuant to our Administration Agreement with Oxford Funds. Mr. Cummins is a Director of ACA Group and performs his functions as our Chief Compliance Officer under the terms of an agreement between us and ACA Group. For the fiscal year ended March 31, 2025, we expensed approximately $120,000 for the fees paid to ACA Group. Timing of Grants of Options The Company did not grant awards of stock options, stock appreciation rights or similar option -likeinstruments during the fiscal year ended March 31, 2025. Accordingly, we have nothing to report under Item 402(x) of Regulation S -K.

17 Reverse Stock Split On July 22, 2025, the Company’s Board of Directors approved a 1 -for-5reverse stock split of the Company’s issued and outstanding shares of Common Stock (the “Reverse Split”). The Reverse Split is expected to be effective as of September 5, 2025, with trading to begin on a split -adjustedbasis at market open on the following business day, September 8, 2025. As a result of the Reverse Split, every five shares of Common Stock will be automatically combined into one